IN2014CH00393A - - Google Patents

Info

Publication number
IN2014CH00393A
IN2014CH00393A IN393CH2014A IN2014CH00393A IN 2014CH00393 A IN2014CH00393 A IN 2014CH00393A IN 393CH2014 A IN393CH2014 A IN 393CH2014A IN 2014CH00393 A IN2014CH00393 A IN 2014CH00393A
Authority
IN
India
Prior art keywords
peptide
support
adhesive layer
cellular immunity
tape preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Yoshiki Maeda
Katsuyuki Okubo
Daisuke Asari
Arimichi Okazaki
takuya Shishido
Mitsuhiko Hori
Haruo Sugiyama
Original Assignee
Nitto Denko Corp
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp, Univ Osaka filed Critical Nitto Denko Corp
Publication of IN2014CH00393A publication Critical patent/IN2014CH00393A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001152Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4242Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN393CH2014 2013-02-05 2014-01-29 IN2014CH00393A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013020798 2013-02-05

Publications (1)

Publication Number Publication Date
IN2014CH00393A true IN2014CH00393A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-04-03

Family

ID=50028734

Family Applications (1)

Application Number Title Priority Date Filing Date
IN393CH2014 IN2014CH00393A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-02-05 2014-01-29

Country Status (8)

Country Link
US (1) US10195258B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2762156A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6512569B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102050931B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN103961305B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2841014A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014CH00393A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2697443C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
CN116253788A (zh) 2013-01-15 2023-06-13 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6512568B2 (ja) * 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用wt1ペプチド癌ワクチン組成物
KR20170055487A (ko) * 2014-10-02 2017-05-19 닛토덴코 가부시키가이샤 경피 투여용 백신 의약 조성물
DE102015119789A1 (de) * 2015-11-16 2017-05-18 Denso-Holding Gmbh & Co. Korrosionsschutzzusammensetzung umfassend Polyisobutylene
US20240024444A1 (en) * 2020-08-07 2024-01-25 Medrx Co., Ltd. Combined Preparation
CN114712493B (zh) * 2022-04-29 2024-05-28 华南理工大学 一种疫苗递送载体及其制备方法和应用
EP4608875A1 (en) * 2022-10-28 2025-09-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-wt1/hla antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE69940264D1 (de) 1998-07-31 2009-02-26 Int Inst Cancer Immunology Inc Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US20040109869A1 (en) * 2001-03-19 2004-06-10 Iomai Corporation Transcutaneous immunostimulation
DE60224508T2 (de) 2001-03-22 2008-12-24 International Institute of Cancer Immunology, Inc., Suita-shi Wti-modifiziertes peptid
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
AU2003242305A1 (en) 2002-06-12 2003-12-31 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptide
AU2003264514A1 (en) 2002-09-20 2004-04-08 Chugai Seiyaku Kabushiki Kaisha Wt1 substitution peptides
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
WO2005045027A1 (ja) 2003-11-05 2005-05-19 International Institute Of Cancer Immunology, Inc. Wt1由来のhla−dr結合性抗原ペプチド
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
JP4887284B2 (ja) 2004-03-15 2012-02-29 デイビッド・ケイ・アール・カラオリス 癌細胞の増殖を阻害するための、または癌細胞のアポトーシスを増大させるための方法
ATE462003T1 (de) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
RU2435782C2 (ru) 2006-02-22 2011-12-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
US20080112974A1 (en) 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
JP4925039B2 (ja) * 2006-09-21 2012-04-25 日東電工株式会社 糖材料の調製方法ならびに糖材料、糖材料を含むマイクロニードルおよびマイクロニードルをそなえてなる経皮製剤
JP2008127277A (ja) * 2006-11-16 2008-06-05 Osaka Prefectural Hospital Organization 免疫賦活化促進剤
EP2980219B1 (en) 2006-12-28 2018-11-14 International Institute of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
WO2008093772A1 (ja) * 2007-01-31 2008-08-07 Hisamitsu Pharmaceutical Co., Inc. 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
AU2008332278C1 (en) * 2007-12-05 2013-10-03 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
WO2011046832A2 (en) * 2009-10-12 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Granulysin in immunotherapy
EP2868325B1 (en) * 2012-07-02 2017-11-01 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
JP6512568B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用wt1ペプチド癌ワクチン組成物
RU2014102938A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Композиция вакцины для трансдермального введения
RU2014102945A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция

Also Published As

Publication number Publication date
KR20140100421A (ko) 2014-08-14
KR102050931B1 (ko) 2019-12-02
CN103961305B (zh) 2019-10-18
RU2697443C2 (ru) 2019-08-14
CA2841014A1 (en) 2014-08-05
CN103961305A (zh) 2014-08-06
RU2014102937A (ru) 2015-08-10
US20140220105A1 (en) 2014-08-07
EP2762156A1 (en) 2014-08-06
JP2014169279A (ja) 2014-09-18
JP6512569B2 (ja) 2019-05-15
US10195258B2 (en) 2019-02-05

Similar Documents

Publication Publication Date Title
IN2014CH00393A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2014CH00396A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2014CH00391A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
CA2924268C (en) Anti-alpha-synuclein antibodies and methods of use
IN2014CH00395A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MY167716A (en) Drive device
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX357202B (es) Composicion de particula tipo virus.
MX2016003876A (es) Métodos y aparatos para suministrar moléculas a través de capas de tejidos.
SG10201805806RA (en) Modulation of Structured Polypeptide Specificity
PH12012501550A1 (en) Modified tuberculosis antigens
EP3150202A4 (en) Drug carrier for tumour-specific targeted drug delivery and use thereof
IN2014DN05885A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
MY191539A (en) Streptococcal vaccine
MX2015011837A (es) Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada.
PH12015501854A1 (en) Factor ix polypeptide formulations
MY165824A (en) Induction Motor and Ceiling Fan Including the Same
IN2014CH00386A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2014CH00390A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP3857574A4 (en) Magnetic levitation
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.